Quick Answer
Guardant Health, Inc. reported R&D Expense of $364.19 million for fiscal year 2025.
Guardant Health, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $364.19M | +4.7% |
| 2024 | $347.75M | -5.3% |
| 2023 | $367.19M | -1.8% |
| 2022 | $373.81M | +42.0% |
| 2021 | $263.22M | +75.6% |
| 2020 | $149.86M | +73.7% |
| 2019 | $86.29M | +70.2% |
| 2018 | $50.71M | +98.4% |
| 2017 | $25.56M | +135.4% |
| 2016 | $10.86M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $89.96M | +3.0% | +2.9% |
| June 30, 2025 | $87.45M | +5.2% | -1.2% |
| March 31, 2025 | $88.52M | +5.6% | +1.4% |
| September 30, 2024 | $87.31M | -7.0% | +5.1% |
| June 30, 2024 | $83.10M | -8.0% | -0.8% |
| March 31, 2024 | $83.80M | -10.0% | -10.7% |
| September 30, 2023 | $93.85M | -6.2% | +3.9% |
| June 30, 2023 | $90.36M | +5.7% | -3.0% |
- Guardant Health, Inc. showed an increase of +4.7% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Guardant Health, Inc.’s r&d expense has grown by 3253.8% (from $10.86 million to $364.19 million).
- The most recent figure is from Guardant Health, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: